LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

LLY

755.74

-0.21%↓

JNJ

152.57

+0.85%↑

UNH

315.59

+8.36%↑

ABBV

185.7

+0.95%↑

NVO

66.94

+4.04%↑

Search

Theravance Biopharma Inc

Open

9.12 -0.11

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.91

Max

9.17

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.8M

-16M

Verkäufe

1.9M

19M

EPS

-0.173

Gewinnspanne

-82.798

Angestellte

97

EBITDA

1.7M

-6.9M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+65.76% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-13M

440M

Vorheriger Eröffnungskurs

9.23

Vorheriger Schlusskurs

9.12

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Theravance Biopharma Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Mai 2025, 23:47 UTC

Market Talk

Nikkei May Trade Rangebound Amid Uncertainty Over U.S. Tariffs -- Market Talk

18. Mai 2025, 23:40 UTC

Market Talk

Gold Rises Amid Concerns Over U.S. Fiscal Deficit -- Market Talk

18. Mai 2025, 18:00 UTC

Ergebnisse

Tax Bill News; Target, Home Depot, and Snowflake Earnings; and More Stock Market News to Watch This Week -- Barrons.com

18. Mai 2025, 17:01 UTC

Top News

GM Is Fighting California on EVs. This Is What It Wants to Overturn and Why. -- Barrons.com

18. Mai 2025, 16:20 UTC

Ergebnisse

Tesla Demand Hasn't Rebounded Yet. Watch China This Week. -- Barrons.com

18. Mai 2025, 12:09 UTC

Top News

Trump Sounds Upbeat on Ukraine Cease-Fire as Russia Unleashes Drone Barrage -- WSJ

17. Mai 2025, 17:15 UTC

Top News

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

17. Mai 2025, 09:30 UTC

Top News
Ergebnisse

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17. Mai 2025, 08:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Mai 2025, 08:20 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

16. Mai 2025, 23:18 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16. Mai 2025, 22:30 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- Update

16. Mai 2025, 21:56 UTC

Market Talk

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16. Mai 2025, 21:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. Mai 2025, 21:54 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- WSJ

16. Mai 2025, 21:22 UTC

Market Talk

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16. Mai 2025, 21:17 UTC

Market Talk

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16. Mai 2025, 21:17 UTC

Top News

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16. Mai 2025, 21:05 UTC

Market Talk

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16. Mai 2025, 20:55 UTC

Akquisitionen, Fusionen, Übernahmen

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16. Mai 2025, 20:50 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

16. Mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. Mai 2025, 20:37 UTC

Top News

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16. Mai 2025, 20:33 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16. Mai 2025, 20:30 UTC

Akquisitionen, Fusionen, Übernahmen

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16. Mai 2025, 20:18 UTC

Top News

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16. Mai 2025, 20:16 UTC

Top News

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16. Mai 2025, 20:15 UTC

Ergebnisse

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16. Mai 2025, 20:11 UTC

Akquisitionen, Fusionen, Übernahmen

Henry Schein: William K. Daniel Joins Board

16. Mai 2025, 20:10 UTC

Akquisitionen, Fusionen, Übernahmen

Henry Schein: Strategic Investment by KKR Completed

Peer-Vergleich

Kursveränderung

Theravance Biopharma Inc Prognose

Kursziel

By TipRanks

65.76% Vorteil

12-Monats-Prognose

Durchschnitt 15.25 USD  65.76%

Hoch 24 USD

Tief 10 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Theravance Biopharma Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

4 ratings

2

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

9.77 / 10.39Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.